Is there an interrelationship between the effects of antipsychotics on psychopathology and on metabolism?

Chukhin, Evgeny; Terevnikov, Viacheslav; Takala, Pirjo; Hakko, Helinä; Putkonen, Hanna; Räsänen, Pirkko; Stenberg, Jan-Henry; Eronen, Markku; Joffe, Grigori

doi:10.3109/08039488.2015.1074283

Cited by 10 publications

(12 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The supplementary search through the reference sections of the identified studies resulted in the inclusion of two additional articles. Thus, a total of 14 studies that reported on the relationship between serum lipids and symptoms of schizophrenia over the course of antipsychotic treatment were retained [8,9,[11][12][13][14][15][16][17][18][19][20][21]. One study was a case report, two were randomized controlled trials, and 11 were observational studies.…”

Section: Resultsmentioning

confidence: 99%

“…Among the studies that reported the association between changes in serum lipids and changes in symptoms (n = 12) [8, 9, 11-16, 18, 19, 21, 22], 9 studies found inverse associations [8, 9, 11-13, 15, 16, 18, 21], whereas three studies did not find significant associations [14,19,22]. The remaining two studies found significant associations but carried out the analysis without using repeated measures of the dependent and independent variables.…”

Section: Resultsmentioning

confidence: 99%

“…It should be noted, however, that Chukhin et al (2016) did not find a significant relationship in 35 male participants treated with clozapine or olanzapine, of whom 18 received orlistat and 17 received placebo [19]. The lack of significant relationship could have been due to the influence of orlistat and a methodological factor.…”

Section: Is the Relationship Specific To Certain Antipsychotics?mentioning

confidence: 94%

“…The lack of significant relationship could have been due to the influence of orlistat and a methodological factor. For instance, the authors did not use a complete dataset for their analysis as they included only the male participants who benefited from orlistat, excluding the 24 female participants who did not [19].…”

Section: Is the Relationship Specific To Certain Antipsychotics?mentioning

confidence: 99%

See 3 more Smart Citations

Association between Serum Lipids and Antipsychotic Response in Schizophrenia

Kim

Barr

Fredrikson

et al. 2019

View full text Add to dashboard Cite

Metabolic abnormalities are serious health problems in individuals with schizophrenia. Paradoxically, studies have noted an association where individuals who gained body weight or who have increased their serum lipids demonstrated a better antipsychotic response. As serum lipids serve as more specific physiological markers than body weight, the objective of this study was to review studies that examined the association between changes in serum lipids and changes in symptoms during antipsychotic treatment in individuals with schizophrenia. A Medline® literature search was performed. Fourteen studies were included and analyzed. Evidence suggests that increases in serum lipids may be associated with decreases in symptoms during antipsychotic treatment. This inverse association may be independent of confounding variables, such as weight gain, and may be most evident during treatment with clozapine. Also, according to recent randomized controlled trials, lipid-lowering agents do not appear to worsen symptoms although this needs to be further investigated in clozapine-treated patients. Future studies should investigate the association in question in a larger population and identify underlying mechanisms.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Is the Relationship Specific To Certain Antipsychotics?mentioning

confidence: 94%

Section: Is the Relationship Specific To Certain Antipsychotics?mentioning

confidence: 99%

See 2 more Smart Citations

Association between Serum Lipids and Antipsychotic Response in Schizophrenia

Kim

Barr

Fredrikson

et al. 2019

View full text Add to dashboard Cite

show abstract

“…In addition, there is a possibility that other factors, not identified in our research, could modulate the metabolic status of our patients. The patient's individual properties could cause particular metabolic patterns [30], as described in a case of olanzapine-induced dyslipidemia and hyperglycemia without an increase in weigh [31].…”

Section: Discussionmentioning

confidence: 99%

Cigarette smoking and heavy coffee drinking affect therapeutic response to olanzapine

et al. 2018

View full text Add to dashboard Cite

introduction/objective Considering relatively complex pharmacokinetic profile of olanzapine, it is expected that certain medications and some compounds, found in food and drink, can induce or inhibit its metabolism. The aim of our study was to investigate the influence of cigarette smoking and heavy coffee consumption on the clinical response to olanzapine. Methods The phase IV, open-labeled, four-week-long prospective clinical trial included 108 adult patients diagnosed with schizophrenia. According to cigarette smoking (n = 52) and coffee drinking (n = 55), four subgroups were defined: non-smokers, non-heavy coffee consumers (group 1), non-smokers, heavy coffee consumers (group 2), smokers, non-heavy coffee consumers (group 3) and smokers and heavy coffee consumers (group 4). Positive and Negative Syndrome Scale (PANSS) and Global Assessment of Functioning (GAF) scales were used for therapeutic response evaluation.

show abstract

Analysis of clinical studies on clozapine from 2012-2022

Freibüchler,

Seifert

2024

Naunyn-Schmiedeberg's Arch Pharmacol

View full text Add to dashboard Cite

Clozapine has been considered the “gold standard” in the treatment of schizophrenia for many years. Clozapine has a superior effect, particularly in the treatment of negative symptoms and suicidal behaviour. However, due to its numerous adverse reactions, clozapine is mainly used for treatment-resistant schizophrenia. The aim of this paper is to analyze the results of clinical studies on clozapine from 2012-2022. PubMed was used as the database. Sixty-four studies were included and categorised by topic. The pharmacokinetic properties of clozapine tablets and a clozapine suspension solution did not differ markedly. Clozapine was superior to olanzapine and risperidone in reducing aggression and depression. A long-term study showed that metabolic parameters changed comparably with olanzapine and clozapine after 8 years. Risperidone and ziprasidone can be used as an alternative to clozapine. Scopolamine, atropine drops, and metoclopramide are effective in the treatment of clozapine-induced hypersalivation. Eight drugs, including liraglutide, exenatide, metformin, and orlistat, are potentially effective in the treatment of clozapine-induced weight gain. Ziprasidone, haloperidol, and aripiprazole showed a positive effect on symptoms when added to clozapine. No investigated drug was superior to clozapine for the treatment of schizophrenia. Ziprasidone and risperidone can also be used well for the treatment of schizophrenia. In the treatment of clozapine-induced hypersalivation and weight gain, some drugs proved to be effective.

show abstract

Is there an interrelationship between the effects of antipsychotics on psychopathology and on metabolism?

Cited by 10 publications

References 19 publications

Association between Serum Lipids and Antipsychotic Response in Schizophrenia

Association between Serum Lipids and Antipsychotic Response in Schizophrenia

Cigarette smoking and heavy coffee drinking affect therapeutic response to olanzapine

Analysis of clinical studies on clozapine from 2012-2022

Contact Info

Product

Resources

About